Study Links Schizophrenia Genetic Risk to Delayed Brain Development and GABA Maturation
Researchers used a novel 'liquidity' metric to track gene expression changes across the lifespan and found that people with high genetic risk for schizophrenia show delayed maturation of brain networks, particularly in GABAergic signaling. The delay occurs in the prefrontal cortex during critical developmental periods but without detectable brain damage, suggesting a developmental pathway from genetic risk to illness. This finding could help explain how genetic vulnerability translates into schizophrenia onset in early adulthood.
A bioRxiv preprint describes a new approach to understanding schizophrenia risk by converting static gene expression snapshots from postmortem brain tissue into dynamic developmental trajectories. Using the 'liquidity' metric to track network evolution across the lifespan, researchers found that neurotypical individuals with elevated polygenic risk scores for schizophrenia exhibited generalized delays in prefrontal cortical development compared to low-risk individuals. The delayed maturation specifically affected GABAergic signaling—the brain's primary inhibitory system—with high-risk individuals showing altered ratios of genes (SLC12A2 and SLC12A5) that regulate chloride ion balance critical for GABA-A receptor function. Notably, this developmental delay was specific to the prefrontal cortex and to schizophrenia risk; it was not observed in the hippocampus or associated with genetic risk for other neuropsychiatric conditions. The findings suggest that genetic risk factors bias early brain development toward a pathogenic trajectory that becomes clinically apparent years later, potentially offering new insights into the biological mechanisms underlying schizophrenia.
What's missing
The study's limitations include reliance on postmortem tissue, which cannot directly measure developmental dynamics in living brains; the cross-sectional nature of the data, which requires inference about longitudinal trajectories; and the need for validation in independent cohorts and prospective studies to establish whether delayed GABA maturation causally contributes to schizophrenia onset or is merely a correlate of genetic risk.
What different sources said
- bioRxivCenter
Liquidity of gene co-expression trajectories across the lifespan highlights delayed maturation and the perinatal GABA switch in schizophrenia risk
Related
Study Identifies Galectin-3's Role in Gastric Metaplasia Development Through Cathartocytosis
Researchers found that galectin-3, a protein upregulated in precancerous tissue changes, facilitates a cellular process called cathartocytosis that promotes the development of spasmolytic polypeptide expressing metaplasia (SPEM) in the stomach. Galectin-3 is abnormally expressed alongside sulfated mucins in high-risk precancerous conditions like Barrett's esophagus and intestinal metaplasia. The findings suggest galectin-3 may represent a therapeutic target for preventing progression from normal tissue to metaplastic and potentially cancerous states.
Study reveals spermatogonial stem cell clones don't follow random drift patterns in zebrafish
Researchers used CRISPR barcoding to track how spermatogonial stem cells (SSCs) contribute to sperm production across a zebrafish's lifetime, finding that clonal dynamics deviate significantly from neutral drift models. The study developed a mathematical framework showing that larger clones tend to drift at higher rates, suggesting non-random selection pressures. These findings have implications for understanding allele transmission and male fertility across the reproductive lifespan.
Researchers identify synthetic lethal TYMS inhibitor effective against ATRX-deficient cells
Scientists developed a phenotype-first screening approach that identified PP12, a covalent fragment that selectively kills ATRX-deficient cells by inhibiting thymidylate synthase (TYMS). The study combines covalent fragment screening, chemoproteomics, and genetic analysis to link drug phenotypes to specific cellular targets. This work establishes a generalizable methodology for discovering synthetic lethal drug candidates in cancer cells with specific genetic deficiencies.